The ATP-binding cassette (ABC) transporter protein multidrug resistance protein 1 (MRP1; ABCC1) plays an important role in the cellular efflux of the high-priority environmental carcinogen arsenic as a triglutathione 
Introduction
Arsenic (As) is a multitarget human carcinogen; chronic exposure is associated with increased incidences of skin, lung, and bladder tumors (Straif et al., 2009 ). More than 100 million people worldwide are chronically exposed to unacceptable levels of nonanthropogenic sources of As [both arsenate (As V ) and arsenite (As III )] in their drinking water, the most common exposure route for adverse health effects (Rahman et al., 2009) . Arsenic compounds are also used in chemotherapy. Arsenic trioxide (As 2 O 3 ) has been approved for treating both newly diagnosed and relapsed acute promyelocytic leukemia, with high remission rates (Emadi and Gore, 2010) . Furthermore, As 2 O 3 and another arsenical, dimethylarsenic glutathione, are in clinical trials for the treatment of multiple hematological and solid tumors (Mann et al., 2009; Emadi and Gore, 2010) .
Arsenic undergoes extensive methylation in humans and most other mammals (Drobná et al., 2010) . It was originally thought that As methylation was a detoxification process because it increases the rate of whole-body clearance of arsenic and the methylated As V species monomethylarsonic acid (MMA V ) and dimethylarsinic acid (DMA V ) are less toxic than As V and As III (Drobná et al., 2010) . However, in vitro studies have revealed that the trivalent methylated species MMA III and DMA III are substantially more potent toxicants than As III , resulting in methylation being viewed as an activation pathway (Kumagai and Sumi, 2007) .
The multidrug resistance protein 1 (MRP1/ABCC1) is an ATPbinding cassette transporter protein that was originally identified based on its ability to confer multidrug resistance in tumor cell lines through an ATP-dependent decrease in cellular drug accumulation (Cole et al., 1992) . MRP1 expression is elevated in a variety of hematological and solid tumors, and it has an important function in clinical anticancer drug resistance . In addition, MRP1 is expressed in nonmalignant tissues and transports a chemically diverse array of endogenous molecules, including GSH and GSSG conjugated organic anions, such as the cholestatic steroid 17␤-estradiol 17-(␤-D-glucuronide) (E 2 17␤G) and the cysteinyl leukotriene 4 . Several substrates of MRP1, including the natural product drugs to which it confers resistance, are not conjugated to any extent in vivo, but their transport is stimulated by GSH . Evidence suggests that at least some of these substrates are coexported with GSH across the plasma membrane.
In addition to anticancer agents and physiological substrates, MRP1 transports many other drugs, carcinogens, and toxicants and is believed to play a protective role by preventing xenobiotic accumulation and resulting toxicity (Leslie et al., 2005) . MRP1 is well known to play an important role in conferring cellular protection against inorganic arsenicals (Cole et al., 1994; Lorico et al., 2002) and transports As III in its triglutathione conjugate form, As(GS) 3 (Leslie et al., 2004) . MRP1 is expressed in most tissues throughout the body; however, its levels are almost undetectable in the healthy human liver . MRP1 localizes to the basolateral surface of epithelia and the apical surface of brain capillaries, generally resulting in the efflux of MRP1 substrates into the blood. Therefore, MRP1 is unlikely to be directly involved in the elimination of arsenic from the body. However, MRP1 is potentially important for preventing the accumulation of arsenicals in certain cell types and tissues. The expression of MRP1 in tumors could also have negative consequences by conferring resistance to arsenic-based chemotherapeutics.
The purpose of the current study was to identify methylated arsenicals that are substrates for MRP1 and characterize the mechanism by which they are transported. MRP1 was found to confer cellular protection against MMA III in a GSH-dependent manner and also reduced MMA III cellular accumulation. Direct transport studies using MRP1-enriched membrane vesicles revealed that MMA III was a substrate for MRP1, but only in the presence of GSH or as MMA III (GS) 2. Transport of MMA III was not supported by ophthalmic acid, a GSH analog lacking a free thiol group, suggesting that the GSH conjugate is the transported form. The transport of MMA III (GS) 2 was then characterized extensively. Cell Lines. The HeLa-vector and HeLa-MRP1 cell lines were gifts from Dr. Susan P.C. Cole (Queen's University, Kingston, ON, Canada) and generated and maintained as described previously . The HeLa-MRP1 stable cell population was checked routinely for MRP1 expression using immunostaining followed by confocal microscopy or fluorescence-activated cell sorting, as described previously . The HEK293 cells were obtained from American Type Culture Collection (Manassas, VA) and cultured in Dulbecco's modified Eagle's medium (Sigma-Aldrich) containing 7.5% fetal bovine serum.
Materials and Methods

Chemicals
Cytotoxicity Testing. HeLa-MRP1 and HeLa-vector cells were seeded in 96-well plates at 1 ϫ 10 4 cells/well and grown for 24 h. In quadruplicate, cells were then treated with As III (0.1-100 M), MMA III (0.1-100 M), DMA III (0.1-100 M), As V (0.001-10 mM), MMA V (0.3-100 mM), or DMA V (0.01-100 mM) for 72 h. To measure the influence of GSH depletion on As III and MMA III cytotoxicity, cells were treated with the ␥-glutamylcysteine synthetase inhibitor BSO (100 M) at the time of seeding and when the arsenicals were introduced. Reduction in cellular GSH levels by BSO was confirmed using the method described previously (Rahman et al., 2006) . HeLa-vector and HeLa-MRP1 cells had cellular GSH levels of 1.8 and 1.1 ng/g protein, respectively, before GSH depletion and 0.1 and 0.03 ng/g, respectively, after BSO treatment. Cell viability was determined using the CellTiter96 AQueous NonRadioactive Cell Proliferation Assay (Promega, Madison, WI) according to the manufacturer's instructions. Data were analyzed using the sigmoidal doseresponse equation in GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA), and EC 50 values were determined. Relative resistance values were calculated as the ratio of the HeLa-MRP1 EC 50 /HeLa-vector EC 50 .
Cellular Accumulation of Arsenic Species. HeLa-vector and HeLa-MRP1 cells were seeded in six-well plates at 5 ϫ 10 5 cells/well and grown for 24 h. Cells were treated with 1 M As III , MMA III , or DMA III in culture media for 24 h. Cells were then washed three times with ice-cold phosphate-buffered saline, trypsinized, pelleted by centrifugation at 1000g for 10 min at 4°C, and then digested with 250 l of concentrated nitric acid for Ͼ48 h. Digested cells were diluted 1:1 with deionized distilled water and filtered through 0.45-m syringe filters (Whatman, Toronto, ON, Canada). The total concentration of arsenic in samples was determined using inductively coupled plasma mass spectrometry (ICP-MS) (Agilent 7500; Yokogawa Analytical Systems, Hachiouji, Japan) using the standard addition method as described previously (Kalivas, 1987) . Samples were introduced directly into the nebulizer of the ICP-MS.
Transient Expression of MRP1 in HEK293 Cells. HEK293 cells were transfected with pcDNA3.1(Ϫ)MRP1 [constructed as described previously )] using the calcium phosphate method as described previously (Carew and Leslie, 2010) . In brief, 3 ϫ 10 6 cells were seeded onto 150-mm plates, and 24 h later, 18 g of DNA was mixed with calcium chloride (250 mM, final volume 1.3 ml) and added dropwise to 1.3 ml of HEPES buffer (275 mM NaCl, 1.5 mM Na 2 HPO 4 , 55 mM HEPES, pH 7.0). The DNA solution was then added dropwise to cells and incubated for 24 h followed by a media change. Seventy-two hours after transfection, cells were washed twice with Tris (50 mM, pH 7.4) sucrose (250 mM) buffer, scraped into 10 ml of Tris sucrose buffer per plate and collected by centrifugation at 800g for 10 min. Cell pellets were stored at Ϫ80°C until membrane vesicles were prepared.
Membrane Vesicle Preparation. Plasma membrane-enriched vesicles were prepared from MRP1 and empty pcDNA3.1(Ϫ)-transfected HEK293 cells, according to previously described methods (Carew and Leslie, 2010) . In brief, cells were thawed and resuspended in buffer containing 250 mM sucrose, 50 mM Tris, pH 7.4, 0.25 mM CaCl 2 , and protease inhibitor tablets. Cells were then disrupted by nitrogen cavitation (pressurized to 200 psi and released to atmospheric pressure), and EDTA (1 mM) was added. The disrupted cells were centrifuged at 800g at 4°C for 10 min to remove unbroken cells and nuclei. The supernatant was layered onto 12 ml of 35% (w/w) sucrose, 50 mM Tris, pH 7.4, and centrifuged at 100,000g for 1 h at 4°C. The interphase containing the plasma membrane-enriched fraction was removed and diluted with 25 mM sucrose, 50 mM Tris, pH 7.4, and centrifuged at 100,000g for 30 min at 4°C. The membranes were washed with Tris sucrose buffer and centrifuged at 100,000g for 30 min at 4°C. The membranes were then resuspended in Tris sucrose buffer by passing through a 27-gauge needle approximately 20 times, then aliquoted and frozen at Ϫ80°C. Expression of MRP1 in membrane vesicles was confirmed by immunoblot analysis, using the rat monoclonal antibody, MRPr1 (1:10,000) (Novus Biologicals, Littleton, CO).
MMA III and MMA III (GS) 2 Transport Assays. MMA III (GS) 2 was synthesized from MMA III and GSH according to previously described methods for As(GS) 3 (Leslie et al., 2004) (GS) 2 -containing transport reactions. At 3 min, transport was stopped by diluting the transport reaction in 800 l of ice-cold Tris sucrose buffer and vesicles pelleted by centrifugation at 100,000g for 20 min. Pelleted membrane vesicles were washed twice with 1 ml of Tris sucrose buffer, digested in 250 l of concentrated nitric acid for 48 h, diluted 1:1 with deionized distilled water, and filtered through 0.45-m syringe filters (Whatman). The total concentration of arsenic in samples was determined using ICP-MS, as described for the cellular accumulation assay.
The influence of GSH (1, 3, or 5 mM) and the GSH analog ophthalmic acid (3 mM) on the transport of MMA III was measured at a 3-min time point. Kinetic parameters of transport were determined by measuring the initial rate of uptake (1-min time point) at eight different concentrations of MMA III (GS) 2 (0.1-10 M). The modulation of MMA III (GS) 2 transport by the MRP1 substrates E 2 17␤G (25 M), GSSG (500 M), and VCR (100 M) was measured at a 1-min time point.
E 2 17␤G Transport Inhibition Assays. Inhibition of E 2 17␤G transport by MMA III (GS) 2 was performed essentially as described previously (Loe et al., 1996a) . In brief, 5 g of membrane vesicles were incubated with [ 3 H]E 2 17␤G (0.1-30 M, 40 -80 nCi), AMP or ATP (4 mM), MgCl 2 (10 mM), creatine phosphate (10 mM), creatine kinase (100 g/ml), GSH (3 mM), GSH reductase (5 g/ml), and NADPH (0.35 mM) at 37°C for 60 s in the absence or presence of MMA III (GS) 2 (25, 40, or 50 M). The transport reaction was stopped by diluting with 800 l of ice-cold Tris sucrose buffer and then filtered through glass fiber filters (type GF/B) using a 96-well plate cell harvester (PerkinElmer Life and Analytical Sciences) and washed five times with Tris sucrose buffer, and radioactivity was quantified by liquid scintillation counting using a Microbeta 2 (PerkinElmer Life and Analytical Sciences). Data were plotted using GraphPad Prism 5 Software, and apparent K m and V max values were determined using Michaelis-Menten analysis. (Cole et al., 1994) . HeLa-MRP1 cells were approximately 3-fold more resistant to MMA III compared with the vector control cell line (Fig. 1B) ; however, no difference in the sensitivity of the cell lines was observed for MMA V , DMA III , or DMA V (Table 1) . To determine whether resistance conferred by MRP1 to As III and MMA III was dependent upon GSH, cytotoxicity was tested after depleting the GSH levels of HeLa-vector and HeLa-MRP1 cells using BSO (100 M). BSO alone had no effect on cell viability. High intracellular GSH levels are known to confer resistance to arsenicals partly through the neutralization of reactive oxygen species (Duechler et al., 2008) . Consistent with this, both arsenicals became significantly more toxic to HeLa-vector and HeLa-MRP1 cell lines after GSH depletion (Tables 1 and 2 ; Fig. 1 (Fig. 3A) . ATPdependent transport of MMA III (1 M) by the MRP1-enriched membrane vesicles was extremely low and similar to transport observed in the presence of AMP or with the vector control membrane vesicles. However, in the presence of GSH (3 mM), ATP-dependent transport of MMA III was observed with an activity of 308 pmol mg Ϫ1 min Ϫ1 . In previous studies, it has been shown that ophthalmic acid and other GSH analogs lacking a free thiol group can substitute for GSH and support the transport of several GSH-dependent MRP1 substrates (Loe et al., 1998; Leslie et al., 2001 Leslie et al., , 2003 Qian et al., 2001; PeklakScott et al., 2005) . These findings indicate that the thiol group of GSH is not required for transport of these substrates and rules out the possibility that formation of a GSH conjugate is critical for the transport to occur. However, ATP-dependent transport of MMA III in the presence of ophthalmic acid (3 mM) was extremely low and similar to ϪGSH conditions or empty vector control (Fig. 3A) . ATP-dependent transport of MMA III (GS) 2 was then measured and found to have an activity of 240 pmol mg Ϫ1 min Ϫ1 . These data suggest that the free thiol group of GSH is required for MMA III transport by MRP1 and are consistent with MMA III (GS) 2 being the transported chemical species.
Results
MRP1 Decreases the
Using similar experimental conditions, transport of DMA III and DMA III (GS) by MRP1-enriched vesicles was measured in the presence of GSH (3 mM). Consistent with the cytotoxicity and accumulation data, no MRP1-dependent transport was observed (data not shown).
MMA III (GS) 2 rapidly dissociates in the absence of physiological concentrations of GSH (1-10 mM) (Kala et al., 2000; Kobayashi et al., 2005; Yehiayan et al., 2009 ). Thus, as stated in Materials and Methods, 3 mM GSH was included in all transport reactions containing MMA III (GS) 2 . Because GSH can stimulate the transport of certain conjugated and unconjugated substrates of MRP1 , the influence of different concentrations of GSH on MMA II -I(GS) 2 transport was evaluated (Fig. 3B ). No significant difference in MMA III (GS) 2 transport was observed in the presence of 1, 3, or 5 mM GSH, concentrations that have been shown previously to stimulate the transport of GSH-dependent substrates in a dosedependent manner (Loe et al., 1996b (Loe et al., , 1998 Renes et al., 1999 III for 24 h. Cells were then harvested and digested with nitric acid, and total arsenic was determined using ICP-MS. Bars represent the means of three independent experiments (ϮS.E.). ‫,ء‬ accumulation is significantly different from HeLa-vector, P Ͻ 0.001 (Student's t test). 
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at ASPET Journals on April 4, 2017 dmd.aspetjournals.org membrane vesicles truly represents transport into the vesicle lumen rather than surface or intramembrane binding, the effect of changes in osmolarity on vesicular uptake was examined. MMA III (GS) 2 (1 M) uptake was decreased as the concentration of sucrose in the transport buffer increased, indicating that the ATP-dependent MMA III (GS) 2 uptake by the vesicles is osmotically sensitive, as expected for a true transport process (Fig. 4A) .
Kinetic Analysis of MRP1-Mediated MMA III (GS) 2 Transport. Time courses of MMA III (GS) 2 (1 M) transport by MRP1-enriched membrane vesicles were completed to determine the linear range of uptake. Transport was linear for up to 3 min with a maximal activity of ϳ900 pmol mg Ϫ1 at 10 min (Fig. 4B ). MRP1-mediated transport was further characterized by determining the initial rates of transport over several concentrations of MMA III (GS) 2 (Fig. 4B ). According to Michaelis-Menten kinetic analysis (GraphPad Prism 5), the average apparent K m and V max values (ϮS.E., n ϭ 3) for MMA III (GS) 2 were 11 Ϯ 2.3 M and 11 Ϯ 0.6 nmol mg Ϫ1 min Ϫ1 , respectively. Inhibition of MMA III (GS) 2 Transport by Various Substrates of MRP1. Several MRP1 substrates, including E 2 17␤G, GSSG, and VCR (ϩGSH) have been shown previously to be competitive inhibitors of MRP1 transport (Leier et al., 1996; Loe et al., 1996a Loe et al., , 1998 . Transport of MMA III (GS) 2 (1 M) was inhibited by E 2 17␤G (25 M), GSSG (500 M), and VCR (100 M) by 57, 75, and 79%, respectively (Fig. 5A ). Inhibitors were used at concentrations shown in previous studies to be at least 5-to 10-fold above their respective K m or K i values to ensure binding site saturation. To determine whether MMA III (GS) 2 and E 2 17␤G have overlapping binding sites on MRP1, the ability of MMA III (GS) 2 to competitively inhibit the transport of E 2 17␤G was evaluated. The inhibition of E 2 17␤G transport by MRP1-enriched membrane vesicles was characterized by measuring the effect of MMA III (GS) 2 (50 M) on E 2 17␤G (0.1-30 M) transport (Fig. 5C) . Michaelis-Menten analysis showed that MMA III (GS) 2 behaved as a competitive inhibitor of E 2 17␤G transport with an average apparent K i value (ϮS.E., n ϭ 3) of 16.3 Ϯ 3.6 M (Fig. 5B) . These data indicate that MMA III (GS) 2 and E 2 17␤G, at minimum, have overlapping binding sites on MRP1.
Discussion
The metalloid arsenic is a multitarget human carcinogen and a major concern as an environmental pollutant. The ubiquitous nature of arsenic in the environment has led to the evolution of arsenic adaptation mechanisms from bacteria to humans (Rosen and Liu, 2009 ). Members of the ABC transporter superfamily subfamily "C" have been shown to be critical for protecting many organisms from arsenic, including Saccharomyces cerevisiae, Leishmania, Arabidopsis, Caenorhabditis elegans, and Danio rerio (Broeks et al., 1996; Dey et al., 1996; Ghosh et al., 1999; Long et al., 2011; Song et al., 2010) . In all of these organisms, ABCC proteins detoxify arsenic either by extrusion from cells or through sequestration within intracellular organelles as thiol conjugates. We have shown previously human MRP1 can transport inorganic arsenic as the triglutathione conjugate As(GS) 3 (Leslie et al., 2004) , but the ability of MRP1 to confer cellular protection to methylated arsenicals was unknown. In the present study, we have found that a HeLa cell line stably expressing MRP1 is capable of conferring a 2.6-fold higher resistance level to MMA III than the HeLa cell line expressing empty vector. Consistent with previously published observations, MRP1 also conferred resistance to As III and As V (Cole et al., 1994) . MRP1 did not confer protection against the pentavalent methylated arsenicals MMA V and DMA V or the trivalent DMA III . GSH depletion has been shown to enhance arsenic trioxide-induced apoptosis (Duechler et al., 2008; Han et al., 2008; Bhalla et al., 2010) . Consistent with this, the toxicities of As III and MMA III were increased upon GSH depletion with BSO for both the HeLa-vector and HeLa-MRP1 cell lines, most dramatically for MMA III ( Fig. 1 ; Table 2 ). In addition, MRP1 resistance levels to As III and MMA III were dependent upon GSH, suggesting a GSH-dependent efflux pathway. We have previously determined that As III is transported by MRP1 as As(GS) 3 (Leslie et al., 2004) , and the next step was to investigate the species of MMA III being transported. Direct transport assays using MRP1-enriched membrane vesicles confirmed that MMA III transport was GSH-dependent. MRP1 is capable of transporting compounds covalently attached to GSH or through a cotransport pathway . Thus, transport of MMA III was measured in the presence of the nonreducing GSH analog ophthalmic acid, known to stimulate the transport of GSH-dependent MRP1 substrates (Loe et al., 1998; Leslie et al., 2001 Leslie et al., , 2003 Qian et al., 2001; Peklak-Scott et al., 2005) . In the case of MMA III , ophthalmic acid did not substitute for GSH; thus, the free sulfur group of GSH was required for transport. These data suggest that MMA III conjugated to GSH is the transported form. Although GSH is best characterized to detoxify arsenicals through neutralization of reactive oxygen species (Flora, 2011) , our data provide further support that formation and efflux of arsenic GSH conjugates are potentially of equal importance.
We have shown previously that the MRP1-dependent transport of As III requires GSH and the glutathione transferase P1 (GSTP1) (Leslie et al., 2004) . It is currently unknown whether the formation of MMA III (GS) 2 under physiological conditions requires catalysis by GSTP1 or a related transferase. In the current study, transport activities for MMA III (GS) 2 and free MMA III in the presence of GSH were very similar (Fig. 3A) . Superficially, these results suggest that MMA III (GS) 2 formation is spontaneous; however, high levels of plasma membrane-associated GSTP1 exist in the HEK293 vesicles used in this study (Qazi et al., 2011) , and although further experimentation is required, GSTP1 could be involved in catalyzing the formation of MMA III (GS) 2 . MMA III (GS) 2 has been isolated from rat bile and mouse urine and, therefore, is formed physiologically and excreted by the liver and kidney (Kala et al., 2000 (Kala et al., , 2004 . Biliary excretion of MMA III (GS) 2 and As(GS) 3 in rats is dependent on the MRP1-related multidrug resistance protein 2 (Mrp2/Abcc2), and these conjugates account for most of the arsenic in bile (Kala et al., 2000) . In mice deficient in ␥-glutamyl transpeptidase, an enzyme responsible for GSH and GSH-conjugate catabolism, approximately 60 to 70% of the urinary arsenic was present as a GSH conjugate (Kala et al., 2004) . Overall, these observations suggest that arsenic-GSH conjugates are the transported forms and account for a major fraction of excreted arsenic. Although rat Mrp2 is important for biliary excretion of MMA III (GS) 2 and As(GS) 3 , these conjugates are unstable at biliary pH resulting in free As III and MMA III and entering the enterohepatic circulation, and urinary excretion is the predominant elimination pathway (Kala et al., 2000 (Kala et al., , 2004 Yehiayan et al., 2009) . Thus, it is critical to understand how extrahepatic tissues handle arsenicals through transport proteins such as MRP1.
We have previously determined that the transport of As(GS) 3 by MRP1-enriched membrane vesicles prepared from the small cell lung cancer cell line H69AR is of high affinity but low capacity with an apparent K m of 0.32 M, V max of 17 pmol mg Ϫ1 min Ϫ1 , and overall efficiency (V max /K m ) of 53 l mg Ϫ1 min Ϫ1 (Leslie et al., 2004 ). In the current study, transport of MMA III (GS) 2 was found to be of high affinity and high capacity with an apparent K m of 11 M, V max of 11,000 pmol mg Ϫ1 min Ϫ1 and overall efficiency (V max /K m ) of 1000 l mg Ϫ1 min Ϫ1 . Thus, the overall efficiency of MMA III (GS) 2 transport is remarkably higher than that for As(GS) 3 . In tissues with sufficient GSH levels, as well as methylation capacity, MRP1 is probably an important detoxification pathway for the highly toxic MMA III . The apparent K m value is of physiological relevance for clinical arsenic exposures. Pharmacokinetic studies of patients undergoing chemotherapy for acute promyelocytic leukemia with As 2 O 3 have plasma levels in the low micromolar range and tissue concentrations would probably exceed this value (Yoshino et al., 2009) .
Despite the 20-fold higher efficiency of transport of MMA III (GS) 2 than As(GS) 3 by MRP1, little difference existed between the resistance level and cellular accumulation of MMA III and As III in the intact HeLa-MRP1 cell line ( Figs. 1 and 2 ; Table 1 ). The whole-cell assay conditions involved a 24-to 72-h exposure of cells to arsenicals, whereas the membrane vesicle experiments measured transport of these conjugates for 1 to 3 min; thus, experimental results are difficult to compare. The chemical instability of the arsenic glutathione conjugates make it probable that, under culture conditions, the cellular protection conferred by MRP1 to either As III or MMA III is underestimated compared with in vivo. Thus, As-GSH conjugates effluxed from the cell would rapidly dissociate in the culture media and the free arsenical taken back up into the cell where it could exert toxicity again. In the in vivo situation, MMA III (GS) 2 or As(GS) 3 transported by MRP1 into the blood would be cleared from the tissue, preventing the reuptake of the intact conjugate or dissociated arsenical.
In contrast with a beneficial detoxification effect of MRP1, its overexpression in hematological and solid tumors could have deleterious consequences by conferring resistance to arsenic-based chemotherapeu- Downloaded from tics, in particular As 2 O 3 . In aqueous solution at physiological pH, As 2 O 3 exists as As(OH) 3 or As III (Liu et al., 2004 , and these metabolites have been shown to be more potent inducers of apoptosis in leukemia and lymphoma cells than As III (Chen et al., 2003) . MRP1 could reduce the cellular concentrations of both inorganic arsenic and MMA III through the efflux of As(GS) 3 and MMA III (GS) 2 and reduce treatment efficacy. To prevent and treat arsenic-induced toxicity and resistance to arsenicbased therapeutics, it is critical to understand the cellular handling of this metalloid. In this study, we have shown that MRP1 reduces the cellular toxicity and accumulation of MMA III through the high-capacity efflux of MMA III (GS) 2 . MRP1 could be essential for preventing toxicity after acute arsenic exposure as well as arsenic carcinogenesis during chronic exposure through the efflux MMA III (GS) 2 . MRP1 is highly polymorphic, and genetic variants could account for some of the well established but poorly understood interindividual susceptibility to arsenic-induced carcinogenesis (Conseil et al., 2005; Hernández and Marcos, 2008) .
